Robert John Steffner

Dr. Robert John Steffner


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
STStefano Testa
Stefano Testa
NBNam Quoc Bui
Nam Quoc Bui
GCGregory Charville
Gregory Charville
RARaffi S. Avedian
Raffi S. Avedian
RSRobert John Steffner
Robert John Steffner
KGKristen N. Ganjoo
Kristen N. Ganjoo
The initial management of desmoid tumors (DTs) is shifting from surgery towards active surveillance, with systemic and locally ablative treatments reserved for enlarging and/or symptomatic disease. However, it remains unclear which patients would benefit most from an initial conservative rather than interventional approach. To answer this question, we retrospectively analyzed adult and pediatric patients with DTs treated at a tertiary academic cancer center between 1992 and 2022. Outcomes measured were progression-free survival (PFS) and time to next treatment (TTNT) after first-line therapy. A total of 262 treatment-naïve patients were eligible for analysis with a median age of 36.5 years (range, 0–87 years). The 5-year PFS and the median TTNT (months) after first-line treatment were, respectively: 50.6% and 69.1 mo for surgery; 64.9% and 149.5 mo for surgery plus adjuvant radiotherapy; 57.1% and 44.7 mo for surgery plus adjuvant systemic therapy; 24.9% and 4.4 mo for chemotherapy; 26.7% and 5.3 mo for hormonal therapy; 41.3% and 29.6 mo for tyrosine kinase inhibitors (TKIs); 44.4% and 8.9 mo for cryoablation and high intensity focused ultrasound; and 43.1% and 32.7 mo for active surveillance. Age ≤ 40 years (p < 0.001), DTs involving the extremities (p < 0.001), a maximum tumor diameter > 60 mm (p = 0.04), and hormonal therapy (p = 0.03) predicted a higher risk of progression. Overall, our results suggest that active surveillance should be considered initially for patients with smaller asymptomatic DTs, while upfront TKIs, local ablation, and surgery achieve similar outcomes in those with more aggressive disease.

2 August 2020 in Skeletal Radiology
Verified
Journal Article
Closed access
PDF file
KKKarin J. Kuhn
Karin J. Kuhn
JCJeffrey M. Cloutier
Jeffrey M. Cloutier
RBRobert Boutin
Robert Boutin
RSRobert John Steffner
Robert John Steffner
GRGeoffrey Riley
Geoffrey Riley

24 February 2022 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
STSeth S Tigchelaar
Seth S Tigchelaar
CFChristopher Frey
Christopher Frey
DSDharshan Sivaraj
Dharshan Sivaraj
NPNicole Segovia Pham
Nicole Segovia Pham
DMDavid G. Mohler
David G. Mohler
RARaffi S. Avedian
Raffi S. Avedian
Leiomyosarcomas (LMS) are a heterogenous group of malignant mesenchymal neoplasms with smooth muscle origin and are classified as either non-uterine (NULMS) or uterine (ULMS). Metastatic pattern, prognostic factors, and ideal staging/surveillance studies for truncal and extremity LMS have not been defined. A retrospective analysis of patients diagnosed with histopathology-confirmed truncal or extremity LMS between 2009 and 2019 was conducted. Data collected included demographics, tumor characteristics, staging, surveillance, and survival endpoints. The primary site was defined as: (1) extremity, (2) flank/Pelvis, or (3) chest wall/Spine. We identified 73 patients, 23.3% of which had metastatic LMS at primary diagnosis, while 68.5% developed metastatic disease at any point. The mean metastatic-free survival from primary diagnosis of localized LMS was 3.0 ± 2.8 years. Analysis of prognostic factors revealed that greater age (≥50 years) at initial diagnosis (OR = 3.74, p = 0.0003), higher tumor differentiation scores (OR = 12.09, p = 0.002), and higher tumor necrosis scores (OR = 3.65, p = 0.026) were significantly associated with metastases. Older patients (≥50 years, OR = 4.76, p = 0.017), patients with larger tumors (≥5 cm or ≥10 cm, OR = 2.12, p = 0.02, OR = 1.92, p = 0.029, respectively), higher differentiation scores (OR = 15.92, p = 0.013), and higher necrosis scores (OR = 4.68, p = 0.044) show worse survival outcomes. Analysis of imaging modality during initial staging and during surveillance showed greater tumor detection frequency when PET imaging was employed, compared to CT imaging (p < 0.0001). In conclusion, truncal and peripheral extremity LMS is an aggressive tumor with high metastatic potential and mortality. While there is a significant risk of metastases to lungs, extra-pulmonary tumors are relatively frequent, and broad surveillance may be warranted.

12 August 2023 in Pediatric Emergency Care
Verified
Journal Article
Open access
SKStephanie Kha
Stephanie Kha
JSJigyasa Ba Sharma
Jigyasa Ba Sharma
DKDeborah Kenney
Deborah Kenney
HDHeike E Daldrup-Link
Heike E Daldrup-Link
RSRobert John Steffner
Robert John Steffner
Objectives: The timely diagnosis of primary bone malignancies in pediatric patients is critical to clinical outcomes. The purpose of this study is to investigate the initial presentation of pediatric bone sarcoma patients to an academic health care system and assess the current interval to diagnosis. Methods: We conducted a retrospective review of pediatric patients (aged 1–18) with biopsy-proven diagnosis of osteosarcoma or Ewing sarcoma presenting between 2004 and 2020. All living patients had 1 year or more of follow-up. Primary outcomes were interval to diagnosis, clinical features on initial presentation, percent of patients with negative radiographic workup at initial presentation, and number of health care encounters before diagnosis. Results: Seventy-one patients (osteosarcoma, 51; Ewing sarcoma, 20) were included. Average age at presentation was 13.1 ± 3.3 years (range, 4.4–18.3). Average symptom duration was 5.4 ± 13.9 months (range, 0.1–84). Clinical features at initial presentation included limb/back pain (91.5% of patients), activity modification/pain medication use (78.9%), palpable mass (40.8%), night pain (35.2%), limp (25.4%), limb disuse (18.3%), and recent fever history (2.8%). Fourteen of 71 patients (19.7%) had negative radiographs at initial presentation. Average number of health care encounters before diagnosis was 1.9 ± 0.6 (range, 1.0–4.0), with most in the outpatient pediatrician clinics (81.2%) and emergency department (18.3%). Average time to diagnosis from initial presentation was 19.5 ± 65 days (range, 0–493); the 14 patients with initial negative radiographs had a statistically significant prolonged interval to diagnosis of 54 ± 134 days (range, 0–493; P = 0.018). Conclusions: We found pediatric patients with primary bone sarcoma present with an average interval to diagnosis of 20 days. Twenty percent of patients had a significantly prolonged interval to diagnosis of 54 days. Clinical features suggest night pain is not a sensitive indicator. In patients of appropriate age with persistent unilateral pain in suspicious locations, early advanced imaging with magnetic resonance imaging should be considered.

2 January 2018 in JBJS Reviews
Verified
Journal Article
Closed access
PDF file
RSRobert John Steffner
Robert John Steffner
EJEugene S. Jang
Eugene S. Jang
NDNicholas C. Danford
Nicholas C. Danford
* Lymphoma can demonstrate primary or secondary involvement of bone. * The most common subtype of primary lymphoma of bone is diffuse large B-cell lymphoma. * 18-fluorodeoxyglucose positron emission tomography with computed tomography (FDG PET/CT) scanning is important for diagnosis, staging, and assessing the response to therapy. * In general, immunochemotherapy should be administered before radiation therapy. * The use of radiation for the treatment of lymphoma of bone is controversial. Recent studies have suggested a benefit in terms of local disease control. * Orthopaedic surgeons see patients who have skeletal lymphoma at the time of initial workup or in consultation for biopsy and/or the assessment of impending and pathological fractures. Correlating the type and stage of bone lymphoma with prognosis can provide a guide to treatment. The goals for patients with a favorable prognosis include minimizing the need for surgery, limiting surgical morbidity when surgery is needed, and using implants that reduce tumor contamination and thus the field size of radiation if needed.

30 April 2025 in Cancers
Verified
Journal Article
Open access
PDF file
LLLauren Jia-Yi Li
Lauren Jia-Yi Li
NBNam Quoc Bui
Nam Quoc Bui
EMEverett J. Moding
Everett J. Moding
RSRobert John Steffner
Robert John Steffner
DMDavid Mohler
David Mohler
MPMinggui Pan
Minggui Pan
Purpose: We investigated care disparities and associated factors along the segments of adult musculoskeletal tumor (MST) care prior to initiation of treatment. Patients and Methods: This cohort included newly diagnosed MST patients who were referred to Stanford Medical Center for establishing care from July 2020 to April 2024. We investigated the interval from the onset of symptoms to the first appointment with a primary care provider (PCP wait-time), and the interval from first PCP appointment to obtaining the first imaging study (imaging wait-time) and to obtaining biopsy results (biopsy wait-time). Sarcoma consult wait-time was defined as the interval between referral date and consult date. We performed a survey among sarcoma physicians and non-physician staff on the perception of wait-time. Results: Among 402 eligible patients, approximately 38.5% had PCP a wait-time longer than 5 weeks, with young adults and Hispanic patients having the highest rate of such long wait-times. Approximately 20.6% of patients had an imaging wait-time longer than 5 weeks, with young adults having the highest proportion of such long wait-times. In addition, Hispanic (p = 0.02), Black (p = 0.05) and Caucasian (p = 0.02) patients had significantly higher percentages of patients with an imaging wait-time of more than 5 weeks compared to Asians. Approximately 79.3% of patients had a biopsy wait-time longer than 5 weeks, with Black and Hispanic patients having the highest percent of such long wait-times. In addition, compared to public insurance, private insurance was associated with a higher proportion of patients with PCP wait-times, imaging wait-times, sarcoma consult wait-times and biopsy wait-times longer than 5 weeks. The survey responses overwhelmingly indicated that a wait-time of more than 5 weeks was not acceptable. Conclusions: Substantial disparities in MST care related to age group, ethnicity and insurance type existed in multiple segments of the care journey prior to the initiation of treatment. Our study provides insights for practice, research and policy considerations for narrowing sarcoma care disparities.